Why don’t drug companies provide access to drug for use in combination with RT?


Session type:


Anthony Chalmers1
1Glasgow Centre for Cancer Research


Clinical evaluation and adoption of novel radiotherapy-drug combinations has failed to keep pace with the exciting scientific discoveries in this area, and is lagging behind the uptake of drug-drug combinations. One reason for this has been the reluctance of pharmaceutical companies to make novel compounds available for evaluation in combination with radiotherapy. This presentation will consider the reasons for this situation and some promising solutions.